Session I: Today's Setting of Drug Development

Risk-benefit Evaluation in Approval of traditional and innovative Drugs (Abstract)

Guidelines for Drug Approval – Today and Tomorrow (Abstract)

Session II: Socioeconomic acpects of new Drugs

What can the Society afford? (Abstract)

Session III: Essential Tools - Today and Tomorrow

Exposure/Response vs. Dose/Response Relationship in Drug Development (Abstract)

Using Bioinformatics for bridging the Genotype-Phenotype Gap (Abstract)

Session IV: Development of Anticancer Drugs

Xeloda, an old cytotoxic in a new Form: new Development Paradigm required? (Abstract)

Safety, Toxicity and Efficacy of Antineoplastic Compounds – a clinical View (Abstract)

Design and Evaluation of clinical Studies with Angiogenesis Inhibitors (Abstract)

Session V: Development of Anti-inflammatory Drugs

Methods to assess the Safety and Efficacy of traditional Compounds (NSAID, Steroids) [Abstract]

Inflammatory Bowel Disease: Cytokines and Cytokine Therapies (Abstract)

Session VI: Development of Anti-Neurodegenerative Drugs

Functional MRI in neurodegenerative Disease (Abstract)

Potential use of PET in Drug Development: labelled Drugs, functional Changes (e.g. Flow and Metabolism), Receptor Occupancy, Dose Response Curves (Abstract)

Session VII: Development of genetically engineered Drugs

Gene- and Immunotherapy in Oncology: Study Concepts, Endpoints and first Results (Abstract)

Tissue Engineering (Abstract)

Stem Cell Therapy (Abstract)

Workshops

QT_c - "Time series data" (Abstract)

Medical Writing – Report Writing (Abstract)

Preclinical requirements to studies in children (Abstract)

Abstracts des Annual Meetings 2003

Annual Meeting of the Association for Applied Human Pharmacology, Volume 2